Terms: = Kidney tumors AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
27 results:
1. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
2. Integrative pan-cancer analysis of mek1 aberrations and the potential clinical implications.
Zhou Z; Peng B; Li J; Gao K; Cai Y; Xu Z; Yan Y
Sci Rep; 2021 Sep; 11(1):18366. PubMed ID: 34526571
[TBL] [Abstract] [Full Text] [Related]
3. Circular RNA DHX33 promotes malignant behavior in ccRCC by targeting miR-489-3p/mek1 axis.
Wang J; Zhang JQ; Zhao XL; Lu JY; Weng ZM; Ding ZM; Yang FQ
Aging (Albany NY); 2020 Jul; 12(14):14885-14896. PubMed ID: 32717723
[TBL] [Abstract] [Full Text] [Related]
4. Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Amoura Z
Blood; 2020 Apr; 135(16):1311-1318. PubMed ID: 32107533
[TBL] [Abstract] [Full Text] [Related]
5. A1CF-promoted colony formation and proliferation of RCC depends on DKK1-MEK/ERK signal axis.
Ni D; Yi Q; Liu J; Hu Y; Lv T; Tan G; Liu Y; Xu L; Xia H; Zhou Q; Xie Y
Gene; 2020 Mar; 730():144299. PubMed ID: 31881249
[TBL] [Abstract] [Full Text] [Related]
6. Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma.
Raspollini MR; Montagnani I; Montironi R; Castiglione F; Martignoni G; Cheng L; Lopez-Beltran A
J Clin Pathol; 2018 May; 71(5):467-471. PubMed ID: 29317515
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites.
Ellens H; Johnson M; Lawrence SK; Watson C; Chen L; Richards-Peterson LE
Drug Metab Dispos; 2017 Jun; 45(6):646-656. PubMed ID: 28320730
[TBL] [Abstract] [Full Text] [Related]
8. Aldosterone activates the oncogenic signals ERK1/2 and STAT3 via redox-regulated mechanisms.
Queisser N; Schupp N; Schwarz E; Hartmann C; Mackenzie GG; Oteiza PI
Mol Carcinog; 2017 Aug; 56(8):1868-1883. PubMed ID: 28272757
[TBL] [Abstract] [Full Text] [Related]
9. The selective mek1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
[TBL] [Abstract] [Full Text] [Related]
10. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
[TBL] [Abstract] [Full Text] [Related]
11. [Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
Qin CP; Liu CL; Zhao YH; Yin HQ; DU YQ; Hu FZ; Sheng ZZ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):590-593. PubMed ID: 29263494
[TBL] [Abstract] [Full Text] [Related]
12. Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma.
Raspollini MR; Castiglione F; Cheng L; Montironi R; Lopez-Beltran A
J Clin Pathol; 2016 Jun; 69(6):547-50. PubMed ID: 26941183
[TBL] [Abstract] [Full Text] [Related]
13. MicroRNA-1826 directly targets beta-catenin (CTNNB1) and mek1 (map2k1) in VHL-inactivated renal cancer.
Hirata H; Hinoda Y; Ueno K; Nakajima K; Ishii N; Dahiya R
Carcinogenesis; 2012 Mar; 33(3):501-8. PubMed ID: 22180573
[TBL] [Abstract] [Full Text] [Related]
14. Graded activation of the mek1/MT1-MMP axis determines renal epithelial cell tumor phenotype.
Mahimkar R; Alfonso-Jaume MA; Cape LM; Dahiya R; Lovett DH
Carcinogenesis; 2011 Dec; 32(12):1806-14. PubMed ID: 21965271
[TBL] [Abstract] [Full Text] [Related]
15. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.
Lin L; Zhong K; Sun Z; Wu G; Ding G
J Cancer Res Clin Oncol; 2012 Jan; 138(1):11-22. PubMed ID: 21947243
[TBL] [Abstract] [Full Text] [Related]
16. ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Cohen JD; Gard JM; Nagle RB; Dietrich JD; Monks TJ; Lau SS
Toxicol Sci; 2011 Nov; 124(1):75-87. PubMed ID: 21813464
[TBL] [Abstract] [Full Text] [Related]
17. Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
Eulitt PJ; Park MA; Hossein H; Cruikshanks N; Yang C; Dmitriev IP; Yacoub A; Curiel DT; Fisher PB; Dent P
Cancer Biol Ther; 2010 Dec; 10(12):1290-305. PubMed ID: 20948318
[TBL] [Abstract] [Full Text] [Related]
18. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.
Bommi-Reddy A; Almeciga I; Sawyer J; Geisen C; Li W; Harlow E; Kaelin WG; Grueneberg DA
Proc Natl Acad Sci U S A; 2008 Oct; 105(43):16484-9. PubMed ID: 18948595
[TBL] [Abstract] [Full Text] [Related]
19. NRF2 as a determinant of cellular resistance in retinoic acid cytotoxicity.
Tan KP; Kosuge K; Yang M; Ito S
Free Radic Biol Med; 2008 Dec; 45(12):1663-73. PubMed ID: 18845239
[TBL] [Abstract] [Full Text] [Related]
20. Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Lee SJ; Lattouf JB; Xanthopoulos J; Linehan WM; Bottaro DP; Vasselli JR
Eur Urol; 2008 Oct; 54(4):845-53. PubMed ID: 18243508
[TBL] [Abstract] [Full Text] [Related]
[Next]
